Last reviewed · How we verify
Lozanoc
At a glance
| Generic name | Lozanoc |
|---|---|
| Also known as | itraconazole |
| Sponsor | Mayne Pharma International Pty Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus (PHASE2)
- Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer (EARLY_PHASE1)
- Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer (PHASE2)
- Topical Itraconazole in Treating Patients With Basal Cell Cancer (EARLY_PHASE1)
- Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis (PHASE2)
- Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg (PHASE4)
- A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lozanoc CI brief — competitive landscape report
- Lozanoc updates RSS · CI watch RSS
- Mayne Pharma International Pty Ltd portfolio CI